Antibody Drug Conjugates Market size is valued at USD 4.84 billion in 2021 and is expected to reach USD 9.87 billion by 2028, at a CAGR of 12.6% during the forecast period 2022-2028. ADCs are a type of biopharmaceutical used to treat cancer that consists of an antibody that selectively targets a tumour antigen and a cytotoxic agent linked together by a chemical linker. ADCs are designed to allow the cytotoxic substance to be targeted specifically to kill cancer cells while having a minimal effect on healthy tissue. Antibody drug conjugates are made up of three parts: an antibody specific for the target associated antigen, an antigen that has limited expression on normal cells, a cytotoxic agent that kills target cancer cells, and a chemical linker that connects the cytotoxic agent to the antibody. Antibody drug conjugates have therapeutic potential but face technological and developmental obstacles. Antibody drug conjugates are thought to be the next generation of therapeutics. They combine the ability of monoclonal antibodies to target specific cells with the ability of cytotoxic medicines to kill those cells. Only with rising technological developments has this technology been able to succeed. Antibody drug conjugates are a new therapeutic class that is attracting the attention of both large and small pharmaceutical businesses. this report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, The global Antibody Drug Conjugates Market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global Market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product opportunities).